

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**POLL RESULTS OF SPECIAL GENERAL MEETING
HELD ON 10 OCTOBER 2011,
INTERIM DIVIDEND PAYMENT
AND
APPOINTMENT OF INDEPENDENT
NON-EXECUTIVE DIRECTOR**

SUMMARY

Special general meeting (“SGM”) of Shandong Weigao Group Medical Polymer Company Limited (the “Company”) was held at 312, Shichang Road, Weihai, Shandong, the People’s Republic of China (the “PRC”) at 9:00 a.m. on 10 October 2011. The Board of the Company (the “Board”) is pleased to announce that all resolutions as set out in the notice of SGM dated 22 August 2011 (the “Notice of SGM”) were duly passed. Terms used in this announcement adopted the same meaning as stated in the Notice of SGM.

* *For identification purpose only*

POLL RESULTS OF SGM

Reference is made to the notice of special general meeting (“Notice of SGM”) of the Company dated 22 August 2011. All resolutions as set out in the Notice of SGM were polled. The poll results of the respective resolutions are as follows:

ORDINARY RESOLUTIONS		No. of votes (%)		Total number of votes present and voting
		FOR	AGAINST	
1.	To consider and approve the appointment of Ms. Fu Mingzhong as an independent non-executive director of the Company; and	3,927,850,076 (99.8%)	8,238,600 (0.2%)	3,936,088,676 (100.0%)
2.	To consider and approve the distribution of interim dividend of RMB0.029 per share for the six months ended 30 June 2011 to be distributed to all shareholders whose names appear on the register of members of the Company on 14 October 2011.	3,936,088,676 (100.0%)	0 (0%)	3,936,088,676 (100.0%)

As more than half of the votes were casted in favour of the ordinary resolutions, all resolutions were duly passed.

As at the date of the SGM, the issued share capital of the Company is RMB447,637,232.4, the holders of these shares were entitled to attend and vote for or against all the resolutions at the SGM, the issued share capital comprising 2,592,640,000 Non-listed Shares and 1,883,732,324 H Shares. There were no shares of the Company entitling the holder to attend and vote only against any of the resolutions at the SGM. The total number of shares entitled to attend and vote in respect of the resolutions at the SGM was 4,476,372,324. Shareholders and authorized proxies holding an aggregate of 4,374,795,884 shares, representing approximately 97.7% of the total issued share capital of the Company, were present at the SGM. The holding of the SGM was in compliance with the requirements of the Company Law of the PRC and the articles of association of the Company. The SGM was chaired by Mr. Zhang Hua Wei, the vice chairman of the Company.

威海朗普聯合會計師事務所有限公司 (Weihai Langpu Lianhe Accounting Company Limited)*, certified public accountants in the PRC was appointed as the scrutineer for the vote-taking of the poll at the SGM of the Company on 10 October 2011.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

With regard to resolution (1) which was duly passed in the SGM, the Board announces that, Ms. Fu Mingzhong (付明仲) (“Ms. Fu”) has been appointed as an independent non-executive director, a member of the audit committee and a member of remuneration committee of the Company with effect from 10 October 2011.

Ms. Fu

Ms. Fu, aged 61, senior economist and associate chief pharmacist and has over 40 years of working experience, particular in the area of management experience in the pharmaceutical and healthcare products industry. Ms. Fu obtained a master’s degree in engineering from the Harbin Institute of Technology in March 1995.

Ms. Fu was previously a workshop director, the head of the quality control office, the office head and the vice factory manager of The Third Harbin Pharmaceutical Factory from June 1972 to March 1999. Ms. Fu was a director of Harbin City Pharmaceutical Group and the general manager of Harbin Pharmaceutical Company Limited from March 1992 to December 1997. She was also a deputy general manager of China Medicines Group (中國醫藥(集團)公司) (currently known as China National Pharmaceutical Group (國藥集團)) from December 1997 to January 1999 and she was a director of China Medicines Group Corporation from January 1999 to July 2009 respectively. Ms. Fu was the executive deputy general manager of China National Pharmaceutical industry Corporation (中國醫藥工業公司) from January 1999 to January 2001. Ms. Fu was the chairman of National Medicines Company Limited (國藥集團藥業股份有限公司), (a company listed on the Shanghai Stock Exchange) from February 2001 to April 2008. Ms. Fu has been a director of Shenzhen Accord Pharmaceutical Company Ltd. (深圳一致藥業有限公司) (a company listed on the Shenzhen Stock Exchange) since April 2008 and was the chairman from April 2008 to December 2008. Ms. Fu has also been a director of Sinopharm Industrial Investment Co., Ltd. (國藥產業投資有限公司) from July 2008 to December 2010. Ms. Fu was the general manager, duty chairman and director of Sinopharm Group Co. Ltd., (國藥控股有限公司), (a company listed on the Hong Kong Stock Exchange) during the period from February 2006 to December 2009, and December 2009 to January 2011 respectively.

Ms. Fu is currently the chairman of China Association of Pharmaceutical Commerce and a member of the Thirteenth Shanghai Municipal People's Congress. Save as disclosed above, Ms. Fu did not hold any positions in the Company or any of its subsidiaries and did not hold any directorships in any other listed companies on the Stock Exchange and any other stock exchange in the three years preceding the date of this announcement.

The Company will enter into a service contract with Ms. Fu for a term of 3 years with effect from 10 October 2011. Her remuneration is fixed at RMB72,000 per annum, which is determined by the Board with reference to her duties and responsibilities within the Company and the prevailing market conditions. Save as director's remuneration disclosed herein, Ms. Fu is not entitled to any other benefits. Ms. Fu had not previously held or currently holds any position in the Company or its subsidiaries and she does not have any relationship with any directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules")).

As at the date of this announcement, Ms. Fu is not connected with any directors, chief executive, substantial shareholders or controlling shareholders of the Company (within the meaning of the Listing Rules). As at the date of this announcement, Ms. Fu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters about the appointment of Ms. Fu as an independent non executive which are required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company.

INTERIM DIVIDEND PAYMENT

Further to the Interim Report with respect to the arrangement of withholding corporate income tax at the rate of 10% before distributing the interim dividend for the six months ended 30 June 2011 to non-resident enterprises (as defined in the Corporate Income Tax Law of the PRC), the Board also wishes to notify the Shareholders of the following details of the payment of the interim dividend. The Company will distribute a pre-tax interim dividend of RMB0.029 per Share for the six months ended 30 June 2010 to all the Shareholders whose names appear on the register of members of the Company on 14 October 2011. According to the Articles, dividends will be denominated and declared in RMB. Dividends on Non-listed Shares will be paid in Renminbi and dividends on H Shares will be paid in Hong Kong dollar. The relevant exchange rate is based on the average middle exchange rate of to Renminbi as quoted by the People's Bank of China for the calendar week preceding 10 October 2011, the date on which the dividend was declared, being HK\$1.00 to RMB0.81655. Therefore, the pre-tax dividend per H Share of the Company, being RMB0.029, will be HK\$0.03552.

The Company has appointed Bank of China (Hong Kong) Trustees Limited as the receiving agent ("Receiving Agent") of the holders of H Shares. The Receiving Agent will dispatch dividends payable to holders of H Shares on or before 4 November 2011 by ordinary mail which shall be posted at the risk of the recipients.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

Weihai, Shandong, the PRC,
10 October 2011

As at the date hereof, the Board comprises of:

Mr. Zhang Hua Wei (*Executive Director*)
Mr. Miao Yan Guo (*Executive Director*)
Mr. Wang Yi (*Executive Director*)
Mr. Wang Zhi Fan (*Executive Director*)
Mr. Wu Chuan Ming (*Executive Director*)
Mr. Chen Xue Li (*Non-executive Director*)
Mrs. Zhou Shu Hua (*Non-executive Director*)
Mr. Li Bing Yung (*Non-executive Director*)
Mr. Jean-Luc Butel (*Non-executive Director*)
Mr. Luan Jian Ping (*Independent non-executive Director*)
Mr. Lo Wai Hung (*Independent non-executive Director*)
Mr. Li Jia Miao (*Independent non-executive Director*)
Ms. Fu Mingzhong (*Independent non-executive Director*)